New pill YR011 enters first human safety trial

NCT ID NCT07285967

Not yet recruiting Knowledge-focused Sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This Phase 1 trial tests the safety and tolerability of a new oral drug called YR011 in 64 healthy volunteers. The drug blocks a potassium channel involved in immune cell activity. Participants receive either YR011 or a placebo in single or multiple doses. The study aims to find out if the drug is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YR011 (also called PA032, a Kv1.3 potassium channel blocker)
What this could lead to: If this early trial shows the drug is safe, it could lead to further studies testing YR011 for conditions involving the immune system, such as autoimmune diseases.
What could go wrong: This is a very early Phase 1 trial with only 64 healthy people. It is designed to check safety, not effectiveness. The drug may cause side effects or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHARMACOKINETICS SAFETY TOLERABILITY

More trials for these conditions

Other studies related to the condition(s) this trial covers.